# DESCRIPTION

## FIELD OF THE INVENTION

- define disease scope

## BACKGROUND OF THE INVENTION

- introduce naltrexone
- describe existing uses
- summarize prior art

## SUMMARY OF THE INVENTION

- claim naltrexone's new role

## DETAILED DESCRIPTION OF THE INVENTION

- introduce naltrexone as antagonist of TLR9
- describe TLR9 location and function
- explain TLR9 recognition of self-nucleic acids in certain pathological conditions
- discuss overactivity of TLR9-mediated signalling
- describe effects of TLR9 overactivity on immune response
- introduce LDN as potential therapy for cancer and supportive care
- explain modulation of immune response by LDN
- describe TLR9-mediated signalling in cancer
- discuss role of TLR9 in cancer microenvironment
- introduce definition of "naltrexone" and its analogues
- define "agonist" and "antagonist"
- define "overexpression of TLR9"
- define "overactivity of TLR9-mediated signalling"
- define "treating" and "treatment"
- define "supportive care"
- define "cancer" and "cancerous"
- define "tumour" or "neoplasm"
- define "tumourigenic"
- define "tumour/cancer microenvironment"
- define "subject"
- define "immunomodulator"
- outline embodiments of the invention

## EXAMPLES

### Example 1—Identification of Naltrexone as an Antagonist of TLR9

- describe screening assays for TLR and NOD transfectants

### Example 2—LDN in the Treatment of Melanoma

- describe patient response to LDN and vitamin D3

### Example 3—LDN in the Treatment of Prostate Cancer

- describe patient response to LDN and Mycobacterium vaccae

